Chemomab Therapeutics (NASDAQ:CMMB) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS

Chemomab Therapeutics (NASDAQ:CMMB) released its quarterly earnings results on Wednesday. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.06), Yahoo Finance reports. During the same quarter last year, the business earned ($0.72) EPS.

Chemomab Therapeutics Stock Performance

Shares of CMMB stock traded up $0.18 during trading hours on Friday, hitting $1.40. 1,688,423 shares of the company were exchanged, compared to its average volume of 175,576. The stock has a market capitalization of $15.47 million, a price-to-earnings ratio of -0.89 and a beta of 0.50. Chemomab Therapeutics has a one year low of $0.42 and a one year high of $1.58. The business’s 50-day simple moving average is $1.07 and its two-hundred day simple moving average is $0.89.

Analysts Set New Price Targets

CMMB has been the subject of a number of analyst reports. Oppenheimer raised shares of Chemomab Therapeutics from a “market perform” rating to an “outperform” rating and set a $6.00 price objective for the company in a research report on Monday, May 6th. Maxim Group raised Chemomab Therapeutics to a “strong-buy” rating in a report on Friday, May 24th.

About Chemomab Therapeutics

Chemomab Therapeutics Ltd., a clinical-stage biotechnology company, discovers and develops therapeutics for the treatment of fibrotic and inflammatory diseases. The company's lead clinical product candidate is CM-101, a humanized monoclonal antibody had completed Phase 2a clinical trials that hinders the basic function of soluble chemokine CCL24 for the treatment of primary sclerosing cholangitis (PSC) and systemic sclerosis (SSc).